VSIR and prostate carcinoma: VISTA enforces inhibitory stimuli to the T cell population under physiological conditions, but an elevation of VISTA expression was found in prostate cancer patients treated with anti-CTLA-4 therapy, being a sign of growing resistance (Hong et al. 2022).